-
Mashup Score: 0Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL - 6 day(s) ago
Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL - 7 day(s) ago
Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL - 11 day(s) ago
Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 51
Abstract. Treatment options for acute myeloid leukemia (AML) have expanded over the last 5 years. New regimens are increasing the options for patients who
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 29
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients with either MRD (≥1 log10 rise) or oligoblastic relapse (blasts 5%-15%) received venetoclax 600 mg once daily D1-28 plus LDAC once daily D1-10 in 28-day cycles. The primary objective was MRD response in the MRD relapse cohort or complete remission (CR/CRh/CRi) in the oligoblastic relapse cohort. RESULTS Forty-eight adults with either MRD (n = 26) or oligoblastic (n = 22) relapse were enrolled. Median age was 67 years (range, 18-80) and 94% had received previous intensive chemotherapy. Patients received a median of four cycles of therapy; 17% completed ≥12 cycles. Patients with oligoblastic relapse had more grade ≥3 anemia (32% v 4%; P = .02) and infections (36% v 8%; P = .03), whereas grade 4 neutropenia (32 v 23%) or thrombocytopenia (27 v 15%) were comparable with the MR
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 22
Neoantigens arising from recurrent AML mutations are immunogenic and represent novel immunotherapeutic targets.IDH2R140Q-specific T cells can selectively e
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies - 23 day(s) ago
Nicosia et al. find that CCS1477 (inobrodib), an EP300/CBP bromodomain inhibitor, induces cell-cycle arrest and differentiation in hematologic malignancy models through disrupting EP300/CBP recruitment to enhancer networks occupied by critical transcription factors. In patients with relapsed/refractory disease, CCS1477 monotherapy induces differentiation responses in AML and objective responses in myeloma.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL @StanfordMed @JCOPO_ASCO #leusm https://t.co/iNdyZGQMcU